

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 13, 2020**

**NextCure, Inc.**

(Exact name of registrant as specified in charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-38905**

(Commission  
File Number)

**47-5231247**

(IRS Employer  
Identification No.)

**9000 Virginia Manor Road, Suite 200  
Beltsville, Maryland**

(Address of principal executive offices)

**20705**

(Zip Code)

**(240) 399-4900**

Registrant's telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01****Regulation FD Disclosure.**

On April 13, 2020, NextCure, Inc. (the “Company”) issued a press release providing an update on the Company’s clinical trial activities due to the impact of the COVID-19 pandemic. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

**Item 9.01****Financial Statements and Exhibits.****Exhibit No.****Description**

99.1 [Press release of NextCure, Inc. dated April 13, 2020.](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 13, 2020

**NEXTCURE, INC.**

/s/ Steven P. Cobourn

\_\_\_\_\_  
Steven P. Cobourn

Chief Financial Officer



## NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic

**BELTSVILLE, Md., April 13, 2020** – [NextCure, Inc.](#) (Nasdaq: NCTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the company's clinical trial activities due to the impact of the COVID-19 pandemic.

“The COVID-19 pandemic has put significant strain on our clinical trial sites, and has raised concerns around monitoring patient safety,” said Michael Richman, NextCure’s president and chief executive officer. “We, like others in our industry, are working closely with our clinical partners and taking the necessary steps to adjust our protocols and timelines as required during this challenging time. We will continue to support ongoing activities for patients enrolled in the Phase 2 portion of our Phase 1/2 NC318 monotherapy trial and will work with trial sites to enroll new patients as appropriate. We have made the decision to delay initiating our NC318 combination trial and NC410 trial until matters improve and look forward to starting these trials. We would like to thank our employees, investigators and clinical sites, patients, collaborators and vendors, who have been strongly supportive during this difficult period and demonstrated great resiliency in the face of new challenges.”

### 2020 Pipeline Updates

Previous guidance is being updated as follows:

- NextCure expects to report initial biomarker data from the Phase 1 portion of its Phase 1/2 NC318 monotherapy trial midyear.
- Due to the COVID-19 pandemic, the company has decided to temporarily delay starting the NC318 combination clinical trial in non-small cell lung cancer with standard-of-care chemotherapies.
- Given the enrollment slowdown, initial data reporting from the Phase 2 portion of the Phase 1/2 NC318 monotherapy clinical trial is expected to be delayed.
- NextCure filed an investigational new drug application for its second product candidate, NC410, received FDA clearance for clinical studies and was prepared to start the Phase 1 portion of a Phase 1/2 clinical trial in March. However, due to the COVID-19 pandemic, the company has decided to temporarily delay initiating that trial.

### About NC318

NC318 is a first-in-class immunomedicine against S15, a novel immunomodulatory target found on highly immunosuppressive cells called M2 macrophages in the tumor microenvironment and on certain tumor types including lung, ovarian and head and neck cancers. In preclinical research, it was observed that S15 promoted the survival and differentiation of suppressive myeloid cells and negatively regulated T cell function, allowing cancer to avoid immune destruction. In preclinical studies, NC318 blocked the negative effects of S15. NextCure believes NC318 has the potential to treat multiple cancer types.

### About NC410

NC410 is a novel immunomedicine that was developed to block LAIR-1-mediated immune suppression by mimicking the natural decoy effects of LAIR-2. LAIR-1 is a co-inhibitory receptor expressed on T cells and dendritic cells. LAIR-2 is a naturally occurring soluble decoy protein for LAIR-1. In preclinical research, it was observed that LAIR-1 inhibited T cell function and dendritic cell activity allowing tumor cells to grow. In preclinical studies, NC410 blocked the negative effects of LAIR-1 to promote T cell function and dendritic cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.

### About NextCure, Inc.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. [www.nextcure.com](http://www.nextcure.com)

### Forward-Looking Statements

This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,” “will,” “potential,” “expects,” “believes,” “intends,” “forward,” “progress,” “continue,” “momentum,” “well-positioned,” “upcoming” and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the progress and expected timing of NextCure’s ongoing clinical trial of NC318 and planned clinical trials of NC318 and NC410, the impact of the COVID-19 pandemic on the initiation, progress or expected timing of those trials and the timing of related data, NextCure’s efforts to adjust trial-related activities to address the impact of the COVID-19 pandemic, NextCure’s plans for further updates related to the impact of the COVID-19 pandemic, and NextCure’s plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the ongoing COVID-19 pandemic on NextCure’s business,

including NextCure's clinical trials, third parties on which NextCure relies and NextCure's operations; NextCure's limited operating history and no products approved for commercial sale; NextCure's need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on NextCure's FIND-IO platform. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including NextCure's Form 10-K filed with the SEC on March 12, 2020. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

**Investor Inquiries**

Timothy Mayer, Ph.D.  
NextCure, Inc.  
Chief Operating Officer  
(240) 762-6486  
[IR@nextcure.com](mailto:IR@nextcure.com)

**Media Inquiries**

Shai Biran, Ph.D.  
MacDougall  
(781) 591-3481  
[NextCure@macbiocom.com](mailto:NextCure@macbiocom.com)